Adagene Inc. (ADAG) Opens Phase 1 Trial of ADG126 Combination in Colorectal Cancer
Adagene Inc. (ADAG) and City of Hope began a Phase 1 trial of ivonescimab and ADG126 for advanced colorectal cancer. The study will include up to 36 patients.
Adagene Inc.
Adagene is a clinical-stage biotechnology company that uses computational biology to discover and develop antibody-based cancer immunotherapies. Its Dynamic Precision Library platform supports three technologies: NEObody for antibody discovery, SAFEbody for antibodies designed to activate mainly in the tumor microenvironment, and POWERbody for engineered antibodies including T-cell engagers. Its lead candidate, ADG126, is an anti-CTLA-4 SAFEbody in clinical development, initially focused on metastatic microsatellite-stable colorectal cancer. The pipeline also includes other clinical, preclinical and discovery-stage candidates. Adagene works with biotechnology and pharmaceutical companies on technology licensing and product-candidate out-licensing, and retains potential participation in product sales through royalties. It also collaborates on clinical development. The company is incorporated in the Cayman Islands and operates through subsidiaries, with research and development activities in China, the United States, Australia and Singapore. Its corporate headquarters is in Suzhou, Jiangsu Province, China.
No SEC Form 4 filings for $ADAG in the last 30 days.
See all $ADAG insider activity →Adagene Inc. (ADAG) and City of Hope began a Phase 1 trial of ivonescimab and ADG126 for advanced colorectal cancer. The study will include up to 36 patients.
Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.
Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ADAG (Adagene Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ADAG coverage spans financial news, insider activity and technology.
Early-stage trial initiation is a modest positive catalyst for ADAG, but it does not yet provide efficacy or safety readouts.
The enrollment completion is a positive milestone that may lift the stock ahead of upcoming data, but the impact is contingent on Phase 3 outcomes.
Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.
The trial start introduces a new catalyst that could lift ADAG if early data are positive.
Positive early data may boost investor sentiment toward ADAG.
AlphAI scores every news story that mentions ADAG with an AI model for sentiment and relevance, and aggregates insider trades from Adagene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adagene Inc. (ADAG) and City of Hope began a Phase 1 trial of ivonescimab and ADG126 for advanced colorectal cancer. The study will include up to 36 patients.
Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.
Chardan Capital kept a Buy rating and $9 price target on Adagene, implying 248.8% upside from the Oct 27 close. The firm cited Adagene's strong immunotherapy pipeline, including ADG126 in clinical trials, and its advanced antibody design technologies.
Adagene Inc. (ADAG) dosed the first patient in a Phase 1 trial for muzastotug and INCA33890 in treating colorectal cancer. Incyte (INCY) sponsors the study under a 2026 collaboration. Muzastotug has FDA Fast Track designation.
Adagene Inc. (ADAG) is developing Muzastotug (ADG126), an immunotherapy for advanced MSS colorectal cancer. Early trials with Keytruda showed promising results, but larger studies are needed. Phase 2 results are expected in early 2027.
Adagene (NASDAQ:ADAG) anticipates Phase II data for its CTLA-4 therapy in MSS colorectal cancer, aiming to replicate Phase Ib response rates of 17-25%. The company plans FDA meetings post-Phase II and potential Phase III trials. Adagene also has a neoadjuvant study in Singapore, with results expected in 2027. It collaborates with Incyte on a combination therapy and has a cash runway into 2028.
HC Wainwright & Co. reiterated a Buy rating on Adagene with a $7 price target, implying a 239.8% upside from the Oct 16 close of $2.06. The firm cited positive clinical developments, including progress in Phase 1 studies for ADG138 and ADG126, and upcoming data readouts for muzastotug in combination with pembrolizumab.
Adagene (NASDAQ: ADAG) announced the clinical development of ADG138, a dual-masked HER2-CD3 T-cell engager using SAFEbody technology. The company expects to begin dosing patients this quarter. Adagene also discussed potential autoimmune applications, partnerships with Third Arc Bio, Sanofi, and Exelixis, and upcoming catalysts, including Phase II data for muzastotug in 2027.
Tam Man Kin (Chief Financial Officer) purchased 2,000 shares of Adagene Inc. (ADAG) at $3.00 on 2026-09-23.
Luo Peter (Chief Executive Officer) purchased 20,290 shares of Adagene Inc. (ADAG) at $3.15 on 2026-09-16.